Full-Time
Posted on 1/17/2025
Develops therapeutics targeting aging mechanisms
$130k - $160kAnnually
Mid, Senior
San Carlos, CA, USA
The job is onsite.
Retro Biosciences focuses on extending healthy human lifespan by developing therapeutics that target the cellular mechanisms of aging. The company operates in the biotechnology sector, addressing the root causes of age-related diseases to help prevent multiple health issues. Its products work by utilizing advanced technologies such as single-cell multi-omics and computational biology to analyze and develop treatments through three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy. Unlike many competitors, Retro Biosciences emphasizes a diversified approach with a balanced pipeline of potential treatments at various development stages. The goal is to reduce healthcare costs associated with aging by providing effective solutions that can lead to healthier lives for individuals.
Company Size
51-200
Company Stage
Seed
Total Funding
$175.1M
Headquarters
Redwood City, California
Founded
2021
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Professional Development Budget
Sam Altman is backing Retro Biosciences with a new funding round of $1 billion to extend human lifespan.
Retro Biosciences, a biotech company backed by OpenAI CEO Sam Altman, plans to raise $1 billion to fund its project aimed at extending human lifespan by 10 years. Altman initially provided $180 million in seed funding and will contribute more in the Series A round.
OpenAI has developed a specialized AI model, GPT-4b Micro, in collaboration with Retro Biosciences, a startup focused on extending human lifespan by ten years.
OpenAI, in partnership with longevity startup Retro Biosciences, has reportedly developed an artificial intelligence model aimed at enhancing the efficiency of stem cell production.
Longevity biotech Retro Biosciences has entered into an $85 million agreement with Multiply Labs to enhance the production of its cell therapies aimed at age-related diseases.